Agenda

Celebrating its 18th year, this year's forum will examine many facets of the evolving relationship between biotech, big pharma, VCs, academia, and payers.

Event Overview

  • Over 40% attendees are SVP level and above
  • 200+ Qualified Deal Markers
  • Editorially driven program lead by Thomson Reuters Recap Analysts
  • Exclusive opportunity to sponsor event at a range of levels. For sponsorship opportunities contact Jillian Tygh at jillian.tygh@thomsonreuters.com.

Tuesday April 29, 2014

7.00 am Continental Breakfast
8.00 am Welcome & Introductions
Eric Walczykowski, Vice President, Life Sciences, Thomson Reuters
8.30 am Keynote Address: The Impact of Healthcare Reform on the Biopharmaceutical Industry
Panelists:
Zeke Emanuel, Joint Appointment, Wharton School & School of Medicine, University of Pennsylvania
Ari Fleischer, Former White House Press Secretary for U.S. President George W. Bush 2001-2003
Paul Hastings, CEO, OncoMed
Moderator:
Jim Greenwood, President and CEO, Biotechnology Industry Organization
9.55 am Analyst Presentation: Looking Back: A Review of the Biopharma Deals
Laura Vitez, Principal Business Analyst, Thomson Reuters
Vinay Singh, Senior Deals Analyst, Thomson Reuters
10.30 am Refreshment Break
11.00 am Panel: “Large and In Charge vs. Small, but Mighty” – Who Makes a Better Licensing Partner: Established Global Pharmaceuticals Companies or Emerging Specialty Pharma and Biotech Players?
Panelists:
George Golumbeski,
Sr. Vice President, BD at Celgene
Jeff Jonker, SVP, Business Development, Theravance
Gary Phillips, Managing Director, Chief Strategy Officer, Mallinckrodt Pharma
James Mackay, President and Chief Operating Officer, Ardea Biosciences and AstraZeneca Global Product VP, Lesinurad
Natalie Holles, SVP, Business Development, Hyperion
Graham Brazier, VP, Business Development, Bristol-Myers Squibb
Moderator:
Chris Ehrlich, Managing Director, Locust Walk Partners
12.00 pm Breakthrough Deal of the Year
Nominees for the Breakthrough Awards will be provided the opportunity to present on their respective deals that have been selected for Deal of the Year.
1.00 pm Keynote Speaker and Networking Lunch: The Evolving Role of Foundations in Drug Development and Deal-making
Tracey Mumford, Senior Associate Director, Research Partnerships, Michael J Fox Foundation
Mark Gordon, Senior Director, CI and BD&L, Thomson Reuters
2.00 pm Presentation: Venture Capital Trends
Vinay Singh, Senior Deals Analyst, Thomson Reuters
2.30 pm Panel: “The Great Divide – Public vs Private Investing in Life
Sciences”
Panelists:
Patrick Heron, General Partner, Frazier Healthcare
Evan McCullough, Portfolio Manager/Analyst, Franklin Templeton

Oleg Nodelman, Managing Director, EcoR1
Srini Akkaraju, General Partner, Sofinnova
Doug Fisher, Partner, InterWest Partners
 
Moderator:

Chris Ehrlich, Managing Partner, Locust Walk Partners
3.15 pm Refreshment Break
3.30 pm Panel: “The Next Gen of biotech”: exploring partnership strategies from a private company CEO’s perspective.
Panelists:
Isaac Ciechanover, CEO, Atara Bio
Laxminarayan Bhat, CEO, Reviva Pharmaceuticals
Sean McCarthy, CEO, CytomX Therapeutics Inc
Moderator:
Eric Long, Founding Principal, ABD Team
4.30 pm Closing Remarks
Eric Walczykowski, Vice President, Life Sciences, Thomson Reuters
5.00 pm Cocktail Reception
Regency Foyer
6.30 pm Awards Dinner
Regency Foyer

Wednesday April 30, 2014

7.30 am Continental Breakfast
8.30 am Keynote Address: How Payers Pick Winners and Losers for their Increasingly Restrictive Formularies
Roger Longman, CEO, RealEndPoints
9.10 am Panel: Leveraging the Public Markets to Finance Development
Panelists:
Paul Hastings, CEO, OncoMed
Robin Smith, CEO, NeoStem
Kenneth Moch, Former President and CEO, Chimerix
Moderator:
Eric Walczykowski, Vice President, Life Sciences, Thomson Reuters
10.40 am Refreshment Break
11.00 am Presentation: Today's IPO Market - How We Got Here, and What's Next
Matthew Rossiter, Partner, Fenwick & West
11.30 am Panel: Today's IPO Market - How We Got Here, and What's Next
Panelists:
Jeff Abbey, CEO, Argos Therapuetics
Robert Dickey - CFO, NeoStem
Kenneth Moch, Former President and CEO, Chimerix
George Milstein, Managing Director, Cowen Group
Matthew Perry, President and Portfolio Manager, BVF Partners
Dave Pritchard, CEO, Kalobios
Moderator:
Matthew Rossiter, Partner, Fenwick & West
12.30 pm Workshop and Networking Lunch: So I’ve been a successful BD Exec - What's Next?
Panelists:
Katrine Bosley, Entrepreneur-in-Residence, The Board Institute
Arlene Morris, CEO, Syndax

Rod Ferguson, Co-Founder, Panorama Capital
Steven James, President and CEO, Labrys Biologics
Juergen Lasowski, Former Executive. Vice President Corporate Development & Strategy, Onyx Pharmaceuticals

Clifford Stocks - Chief Executive Officer, Theraclone Sciences
Moderator:
Kevin Kwok – Head of Talent Acquisition and Strategy, Theravance
1.45 pm Presentation:Partnering Returned Assets: Understanding Strategies to Maximize Value
Jay Mohr, Managing Director, Locust Walk Partners
2.15 pm Panel: Partnering Returned Assets: Understanding Strategies to Maximize Value
Panelists:
Steve James, President and CEO, Labrys Biologics
Tom King, President and CEO, Alexza Pharmaceuticals
Mark Baker, CEO, Progenics Pharmaceuticals
Richard Brudnick, VP and Co-Head of Business Development, Biogen Idec
Natalie Holles, SVP, Business Development, Hyperion
Moderator:

Jay Mohr, Managing Director, Locust Walk Partners
3.00 pm Refreshment Break
3.15 pm Presentation: M&A Transaction Data
Jon Norris, Managing Director, SVB Capital
3.30 pm Panel: Puttin' a Ring on it - M&A Transactions
Panelist:
Jon Norris, Managing Director, SVB Capital
James Mackay, President and Chief Operating Officer, Ardea Biosciences and AstraZeneca Global Product VP, Lesinurad
Carol Gallagher, Venture Partner, Frazier Healthcare
Heath Lukatch, Partner, Novo Ventures

Moderators:
Effie Toshav, Partner, Fenwick & West
4.15 pm Panel: Bull or Bear – what does the future hold for the next generation of dealmakers?
Panelists:
Luke Timmerman, Biotechnology Journalist 
Adam Feuerstein, Senior Columnist, TheStreet
Ron Leuty, Reporter, San Francisco Business Times
Peter Winter, Editor, BioWorld Insight, Thomson Reuters
Moderator:
Eric Walczykowski, Vice President, Life Sciences, Thomson Reuters
5.00 pm Cocktail Reception
Regency Foyer

For a full list of confirmed speakers click here. Check back regularly for more confirmed speakers.

Twitter
LinkedIn
Blog

Join the conversation on Twitter: #Allicense2014

Syndax